Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab extension study in active rheumatoid arthritis
2008-006924-68Phase 3Terminated
- Sponsor
- Roche
- Start
- Jan 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of tocilizumab in rheumatoid arthritis (RA) (2 arms), sponsored by Roche. Primary endpoint: Incidence of adverse events and serious adverse events. Started Jan 2009; status: terminated.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2008-006924-68.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006924-68.